Effectiveness of Cuban Medication HEBERPAG in Holguin
- Written by Lourdes Pichs Rodríguez
- Published in Holguin
- Hits: 1632

Dr. Yanelis Pereda Mayedo, head of project at the Holguin Oncology Center, explained that between 2012 and 2016 the province included 40 patients from 30 to 80 years of age in the clinical trial with a CBC histological clinical diagnosis of any location, showing effectiveness of the medicine in the treatment of non-melanoma skin tumors of any subtype, size, and location.
"So far there is an adequate quality of healing, as it is determined by the color, texture, volume and sensitivity of the lesions; in the majority of patients, the skin is flat or with slight hypotrophy and 10 percent with slight hypochromia. "
Dr. Pereda explained that this unique product of its kind in the world is applied to all patients from the territory referred to the Oncology Center. "The injectable medicine is applied three times a week for three consecutive weeks, with subsequent monitoring every four years and if necessary there is a second cycle.”
She said the Heberferon product of the Center for Genetic Engineering and Biotechnology (CIGB) of Havana combines Interferon Alfa 2 b with recombinant human Gamma, as a therapeutic procedure in Oncology for the treatment of skin cancer in patients, who first only had surgery as the only alternative, often with significant skin mutilations on the face, neck and scalp.
In 2017, more than a thousand patients with skin cancer were reported in the Oncology Center, mostly male, although the incidence increases every year in women both incorporated into work and housewives.
The doctor stressed the need to protect themselves from ultraviolet rays, from the aggressiveness of our climate, “because most of the time we do not protect our skin as we should before the intensity of sunlight.”